Document is current

Article History

Received: 29 August 2024

Accepted: 20 November 2024

First Online: 18 December 2024

Declarations

:

: The protocol was approved by the sites' institutional review boards and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.

: Not applicable; no individual patient data are included.

: TPH received research funding from Novartis, and Bristol Myers Squibb, and consultancy fees from Novartis, Takeda, Terns Pharmaceuticals, Enliven Therapeutics, and Ascentage Pharma. JG has received payment for consultancy from Novartis and Incyte. He is a committee member of the European Hematologic Association. He reports grants to his patient advocacy organization from Novartis, Pfizer, Bristol Myers Squibb, Incyte, Takeda, and Terns Pharmaceuticals. D-WK received research funding from Novartis, Bristol Myers Squibb, Enliven, Korea Otsuka, Il-Yang, and PharmaEssentia; honoraria from Novartis, Bristol Myers Squibb, Enliven, Krea Otsuka, and Il-Yang; and speaker bureau fees from Novartis, Bristol Myers Squibb, Korea Otsuka, and Il-Yang. EL received personal fees from Novartis, and Pfizer and is a member of speakers bureaus for Novartis, Pfizer, and Fusion Pharma. JM received research funding from BeiGene. AT received personal fees from Novartis, Pfizer, and R-Pharma and is a member of the speakers bureaus for Novartis, Pfizer, and R-Pharma. JEC received research funding from AbbVie, Ascentage Pharma, Novartis, and Sun Pharma and consultancy fees from Lilly, Nerviano, Novartis, Pfizer, Rigel, Sun Pharma, Syndax, and Biopath Holdings. He holds stock options in and is a board member of Biopath Holdings. BN, and SQ are employees of Novartis. APC and SK are employees and shareholders of Novartis stock. GS declares no competing interests.